Antibacterial Activity of LCB10-0200 against Klebsiella pneumoniae
Autor: | Jin-Hwan Kwak, Kyuman Oh, Young-Lag Cho, Hee-Soo Park, Sang-Hun Oh, Young-Rok Kim |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Microbiology (medical)
siderophore medicine.drug_class Klebsiella pneumoniae Cephalosporin Antibiotics cephalosporin Ceftazidime RM1-950 Biochemistry Microbiology In vivo medicine Pharmacology (medical) General Pharmacology Toxicology and Pharmaceutics Pathogen Antibacterial agent biology business.industry LCB10-0200 biology.organism_classification Infectious Diseases Therapeutics. Pharmacology business Antibacterial activity medicine.drug |
Zdroj: | Antibiotics, Vol 10, Iss 1185, p 1185 (2021) Antibiotics Volume 10 Issue 10 |
ISSN: | 2079-6382 |
Popis: | Klebsiella pneumoniae is one of the important clinical organisms that causes various infectious diseases, including urinary tract infections, necrotizing pneumonia, and surgical wound infections. The increase in the incidence of multidrug-resistance K. pneumoniae is a major problem in public healthcare. Therefore, a novel antibacterial agent is needed to treat this pathogen. Here, we studied the in vitro and in vivo activities of a novel antibiotic LCB10-0200, a siderophore-conjugated cephalosporin, against clinical isolates of K. pneumoniae. In vitro susceptibility study found that LCB10-0200 showed potent antibacterial activity against K. pneumoniae, including the beta-lactamase producing strains. The in vivo efficacy of LCB10-0200 was examined in three different mouse infection models, including systemic, thigh, and urinary tract infections. LCB10-0200 showed more potent in vivo activity than ceftazidime in the three in vivo models against the drug-susceptible and drug-resistant K. pneumoniae strains. Taken together, these results show that LCB10-0200 is a potential antibacterial agent to treat infection caused by K. pneumoniae. |
Databáze: | OpenAIRE |
Externí odkaz: |